camostat has been researched along with Acute Disease in 13 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofloxacin is considered to be a safe and effective treatment for acute infectious colitis." | 7.80 | Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. ( Cheung, DY; Cho, HJ; Cho, SH; Kim, JI; Kim, JK; Kim, SS; Lee, HJ; Sung, HY, 2014) |
| "The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals." | 7.68 | Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "The effect of peritoneal lavage with the addition of camostate to the lavage fluid on the outcome of taurocholate pancreatitis in rats was studied." | 7.68 | Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. ( Creutzfeldt, W; Fussek, M; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1990) |
| "Two models of severe acute pancreatitis were chosen and pancreatitis induced by sodium taurocholate and by a choline-deficient ethionine-supplemented diet, to evaluate the effectiveness of FOY-305 (camostate), a new synthetic trypsin inhibitor." | 7.67 | Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. ( Göke, B; Gröne, HJ; Lankisch, PG; Otto, J; Pohl, U; Rahlf, G; Wereszczynska-Siemiatkowska, U, 1989) |
| "Comparing the two groups of acute pancreatitis patients after 6 days of treatment with gabexate mesilate, we observed a statistically significantly lower alpha-amylase activity in the serum of treated patients compared with the placebo group." | 5.27 | Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis. ( Freise, J; Magerstedt, P; Schmid, K; Schmidt, FW, 1985) |
| "Ciprofloxacin is considered to be a safe and effective treatment for acute infectious colitis." | 3.80 | Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. ( Cheung, DY; Cho, HJ; Cho, SH; Kim, JI; Kim, JK; Kim, SS; Lee, HJ; Sung, HY, 2014) |
| "Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively." | 3.69 | Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. ( Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E, 1997) |
| "The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals." | 3.68 | Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| " Caerulein-induced pancreatitis or treatment with the synthetic protease inhibitor camostate had no significant effects on permeability." | 3.68 | Pancreatic microvascular permeability in caerulein-induced acute pancreatitis. ( Mann, GE; Sweiry, JH, 1991) |
| "The effect of peritoneal lavage with the addition of camostate to the lavage fluid on the outcome of taurocholate pancreatitis in rats was studied." | 3.68 | Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. ( Creutzfeldt, W; Fussek, M; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1990) |
| "Two models of severe acute pancreatitis were chosen and pancreatitis induced by sodium taurocholate and by a choline-deficient ethionine-supplemented diet, to evaluate the effectiveness of FOY-305 (camostate), a new synthetic trypsin inhibitor." | 3.67 | Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. ( Göke, B; Gröne, HJ; Lankisch, PG; Otto, J; Pohl, U; Rahlf, G; Wereszczynska-Siemiatkowska, U, 1989) |
| "Comparing the two groups of acute pancreatitis patients after 6 days of treatment with gabexate mesilate, we observed a statistically significantly lower alpha-amylase activity in the serum of treated patients compared with the placebo group." | 1.27 | Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis. ( Freise, J; Magerstedt, P; Schmid, K; Schmidt, FW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sung, HY | 1 |
| Kim, JI | 1 |
| Lee, HJ | 1 |
| Cho, HJ | 1 |
| Cheung, DY | 1 |
| Kim, SS | 1 |
| Cho, SH | 1 |
| Kim, JK | 1 |
| Inoue, N | 1 |
| Ito, T | 1 |
| Akashi, T | 1 |
| Kawabe, K | 1 |
| Oono, T | 1 |
| Gibo, J | 1 |
| Arita, Y | 1 |
| Nawata, H | 1 |
| Funakoshi, A | 1 |
| Taniguchi, H | 1 |
| Yomota, E | 1 |
| Kume, E | 1 |
| Shikano, T | 1 |
| Endo, T | 1 |
| Nagasaki, M | 1 |
| Yuasa, C | 1 |
| Irimura, K | 1 |
| Oda, M | 1 |
| Fukui, K | 1 |
| Oka, T | 1 |
| Otsuki, M | 1 |
| Tani, S | 1 |
| Okabayashi, Y | 1 |
| Fuji, M | 1 |
| Nakamura, T | 1 |
| Fujisawa, T | 1 |
| Itoh, H | 1 |
| Yoshida, K | 1 |
| Toki, F | 1 |
| Takeuchi, T | 1 |
| Takeda, K | 1 |
| Sweiry, JH | 1 |
| Mann, GE | 1 |
| Leonhardt, U | 1 |
| Seidensticker, F | 1 |
| Fussek, M | 1 |
| Stöckmann, F | 1 |
| Creutzfeldt, W | 1 |
| Freise, J | 1 |
| Schmidt, FW | 1 |
| Magerstedt, P | 1 |
| Schmid, K | 1 |
| Redmond, HP | 1 |
| Leahy, AL | 1 |
| Keane, FB | 1 |
| Tanner, WA | 1 |
| Lankisch, PG | 1 |
| Pohl, U | 1 |
| Göke, B | 1 |
| Otto, J | 1 |
| Wereszczynska-Siemiatkowska, U | 1 |
| Gröne, HJ | 1 |
| Rahlf, G | 1 |
| Yamasaki, Y | 1 |
| Kuroshima, T | 1 |
| Tsuji, K | 1 |
| Kawamoto, H | 1 |
| Higashimoto, Y | 1 |
13 other studies available for camostat and Acute Disease
| Article | Year |
|---|---|
Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infectio | 2014 |
Acute pancreatitis in the early stages of pregnancy associated with a PSTI gene mutation.
Topics: Abdominal Pain; Acute Disease; Adult; Amino Acid Substitution; Amylases; Carrier Proteins; Diet, Fat | 2004 |
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate | 1997 |
Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
Topics: Acute Disease; Administration, Oral; Amylases; Animals; Ceruletide; Esters; Ethanol; Gabexate; Guani | 1999 |
Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Esters; Gabexate; Guanidines; Male; Organ Size; Pancre | 1990 |
[Antienzyme preparations in the treatment of acute pancreatitis].
Topics: Acute Disease; Adult; Aprotinin; Benzamidines; Cytidine Diphosphate Choline; Disseminated Intravascu | 1990 |
[Protease inhibitors in the treatment of pancreatitis].
Topics: Acute Disease; Animals; Aprotinin; Chronic Disease; Esters; Gabexate; Glycoproteins; Guanidines; Hum | 1991 |
Pancreatic microvascular permeability in caerulein-induced acute pancreatitis.
Topics: Acute Disease; Animals; Capillary Permeability; Ceruletide; Edetic Acid; Endothelium, Vascular; Este | 1991 |
Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis.
Topics: Acute Disease; Animals; Esters; Gabexate; Guanidines; Male; Pancreatitis; Peritoneal Lavage; Proteas | 1990 |
Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.
Topics: Acute Disease; alpha-Amylases; Aprotinin; Esters; Gabexate; Guanidines; Humans; Infusions, Parentera | 1985 |
Effect of FOY-305 (Camostate) on severe acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Disease Models, Animal; Esters; Gabexate; Guanidines; Pancreatitis; Rats; Ra | 1989 |
Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Choline Deficiency; Esters; Female; Gabexate; Guanidines; Male; Mice; Pancre | 1989 |
[Protective effect of camostat mesilate and allopurinol in acute edematous pancreatitis in the rat induced by excessive doses of caerulein].
Topics: Acute Disease; Allopurinol; Animals; Ceruletide; Edema; Esters; Gabexate; Guanidines; Male; Pancreat | 1987 |